首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1510篇
  免费   70篇
  国内免费   113篇
儿科学   64篇
妇产科学   13篇
基础医学   164篇
口腔科学   28篇
临床医学   188篇
内科学   347篇
皮肤病学   41篇
神经病学   122篇
特种医学   364篇
外国民族医学   1篇
外科学   71篇
综合类   40篇
预防医学   63篇
眼科学   24篇
药学   80篇
中国医学   1篇
肿瘤学   82篇
  2021年   6篇
  2020年   6篇
  2019年   11篇
  2018年   18篇
  2016年   20篇
  2015年   21篇
  2014年   18篇
  2013年   43篇
  2012年   19篇
  2011年   36篇
  2010年   50篇
  2009年   50篇
  2008年   33篇
  2007年   71篇
  2006年   30篇
  2005年   56篇
  2004年   17篇
  2003年   25篇
  2002年   21篇
  2001年   21篇
  2000年   33篇
  1999年   26篇
  1998年   92篇
  1997年   95篇
  1996年   104篇
  1995年   66篇
  1994年   63篇
  1993年   65篇
  1992年   12篇
  1991年   37篇
  1990年   29篇
  1989年   52篇
  1988年   43篇
  1987年   52篇
  1986年   33篇
  1985年   45篇
  1984年   21篇
  1983年   18篇
  1982年   27篇
  1981年   24篇
  1980年   32篇
  1979年   12篇
  1978年   13篇
  1977年   22篇
  1976年   27篇
  1975年   15篇
  1972年   5篇
  1970年   8篇
  1968年   6篇
  1921年   4篇
排序方式: 共有1693条查询结果,搜索用时 0 毫秒
31.
32.
A human malignant melanoma cell line (M3Dau) was observed by electron microscopy to interact directly with human platelets and induced platelet aggregation. Fab fragments of a monoclonal antibody MoAb (LYP18), directed against the platelet glycoprotein (GP) IIb-IIIa complex, inhibited platelet-melanoma interactions and platelet-platelet aggregation. M3Dau melanoma cells bind LYP 18 and synthesize IIb-IIIa- like GPs. When the melanoma cells were preincubated with LYP 18, tumor- platelet interaction did not occur, suggesting that the interaction may be mediated by the IIb-IIIa-like GPs present on the melanoma cell surface. Glanzmann's thrombasthenic platelets, lacking GPIIb and IIIa, did not interact with melanoma cells, indicating that the platelet GPIIb-IIIa complex is also necessary for the platelet-melanoma cell interaction. This work demonstrates the importance of the IIb-IIIa-like GPs, present on M3Dau melanoma cells, in mediating tumor-platelet interactions.  相似文献   
33.

Objective

To examine hypertension management across countries and over time using consistent and comparable methods.

Methods

A systematic search identified nationally representative health examination surveys from 20 countries containing data from 1980 to 2011 on blood pressure measurements, the diagnosis and treatment of hypertension and its control with antihypertensive drugs. For each country, the prevalence of hypertension (i.e. systolic blood pressure ≥ 140 mmHg or antihypertensive use) and the proportion of hypertensive individuals whose condition was diagnosed, treated or controlled with medications (i.e. systolic pressure < 140 mmHg) were estimated.

Findings

The age-standardized prevalence of hypertension varied between countries: for individuals aged 35 to 49 years, it ranged from around 12% in Bangladesh, Egypt and Thailand to around 30% in Armenia, Lesotho and Ukraine; for those aged 35 to 84 years, it ranged from 20% in Bangladesh to more than 40% in Germany, the Russian Federation and Turkey. The age-standardized percentage of hypertensive individuals whose condition was diagnosed, treated or controlled was highest in the United States of America: for those aged 35 to 49 years, it was 84%, 77% and 56%, respectively. Percentages were especially low in Albania, Armenia, the Islamic Republic of Iran and Turkey. Although recent trends in prevalence differed in England, Japan and the United States, treatment coverage and hypertension control improved over time, particularly in England.

Conclusion

Globally the proportion of hypertensive individuals whose condition is treated or controlled with medication remains low. Greater efforts are needed to improve hypertension control, which would reduce the burden of noncommunicable diseases.  相似文献   
34.
Deficient confrontation naming has been observed in a number of neurological illnesses, as well as in aphasia and normal aging. The Visual Naming Test (VNT) of the Multilingual Aphasia Examination (MAE) is a standardized measure of confrontation naming. One hundred patients, consecutively referred for neuropsychological evaluation, were administered the VNT, Boston Naming Test (BNT), and WAIS-R. Concurrent validity of the two confrontation naming measures was demonstrated by their high intertest agreement. Performance on the VNT was found to be related to a unique ability separate from general intellectual functioning. Suggestions regarding the clinical use of the VNT are discussed.  相似文献   
35.
36.
37.
38.
39.
Adynamia episodica hereditaria: What causes the weakness?   总被引:2,自引:0,他引:2  
The cause of weakness was investigated in a patient with adynamia episodica hereditaria without myotonia. A pattern of exercise and rest produced episodes of hyperkalemic periodic paralysis. In addition, local muscle weakness was induced by forearm cooling. Investigations on isolated intercostal muscle demonstrated that a high potassium concentration in the bathing solution triggered a noninactivating membrane current causing depolarization of the muscle fibers. This current was carried by sodium as it could be inhibited by tetrodotoxin. The abnormal sodium conductance led to an increase of sodium within the fibers. This was demonstrated directly by intracellular recordings. Weakness induced by rest after exercise and cold-induced weakness appeared to have different pathomechanisms. In the cold, the muscle fibers retained a normal resting potential, but their excitability was reduced and their mechanical threshold was increased. These findings also provide evidence that the mechanism of cold-induced weakness in adynamia episodica is distinctly different from the cold-induced weakness that occurs in paramyotonia congenita.  相似文献   
40.
AMP-18,一种新发现的胃黏膜保护因子   总被引:3,自引:0,他引:3  
AMP-18是一种新发现的由胃腺体上皮细胞合成的小分子蛋白质,独特表达于胃黏膜,机体其他部位少见,胃癌组织中表达缺失.AMP-18 由185个氨基酸组成,除去N端信号肽(20个氨基酸)后大小约18 ku,第54-150个氨基酸组成高度保守的结构域(BRICHOS区域)承担主要的生理功能.AMP-18由胃腺体上皮细胞以胞吐的方式分泌到胃黏液中,他的合成和分泌与个体生长发育有关,并受福斯高林、吲哚美辛、地塞米松等药物的影响.目前发现 AMP-18的生理功能主要有促进胃黏膜上皮细胞的有丝分裂,促进细胞的迁徙,促胃肠黏膜损伤的修复,保持胃肠黏膜的完整等.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号